News & Events : Press Releases
October 11, 2016
FORMA THERAPEUTICS APPOINTS JIM WINKLER, Ph.D., VICE PRESIDENT, DISCOVERY AND TRANSLATIONAL BIOLOGY
WATERTOWN, Mass. – October 11, 2016 – FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Jim Winkler, Ph.D., as Vice President, Discovery and Translational Biology. Dr. Winkler joins the FORMA leadership team with over 30 years’ experience in the biotechnology and pharmaceutical industry within oncology and inflammation, and most recently served as Chief Scientific Officer at Arvinas, Inc., in New Haven, CT.
“Jim’s impressive track record of accomplishments, most notably the discovery and advancement of 16 drugs into clinical development, with several demonstrating mid-to-late stage clinical success, provides FORMA with additional experienced leadership to cultivate and manage our broad therapeutic pipeline,” said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. “Throughout his career, Jim has emphasized capability, quality and culture as interdependent areas of priority for high performing teams. His contributions and expertise across target validation and early drug discovery, translational medicine and early clinical development, innovative platform development, and fostering collaborative interactions will no doubt influence the future directions of our discovery portfolio and distributed partnership network.”
Jim Winkler, Ph.D., commented, “I am excited to join the FORMA team. The company has an exceptional culture, inspirational leadership, and creative scientific talent both internally and across their collaborative relationships. I believe this empowering and engaging environment sets the stage for success and creates the potential to deliver new medicines offering profound benefit to patients.”
Prior to joining FORMA, Jim held various leadership positions at McNeil Pharmaceuticals, GlaxoSmithKline, Array Biopharma and Arvinas. Most recently at Arvinas, Jim was responsible for platform advancement and the discovery of therapeutic compounds targeting specific proteins for degradation. From 2002 through 2013, at Array Biopharma, Jim provided leadership for teams working in drug discovery, translational research and clinical development, as well as having managed several collaborations with multinational pharmaceutical firms. His contributions included building a pipeline of development drugs with over twelve having advanced toward Phase II or III studies to date.
Jim received a bachelor’s degree in biochemistry from Princeton University, Princeton, New Jersey, and a Ph.D. in pharmacology from Medical College of Pennsylvania, Philadelphia, Pennsylvania. He completed a post-doctoral fellowship in molecular pharmacology with Stanley Crooke, M.D., Ph.D., at Smith Kline and French Laboratories. To date, he has authored more than 120 patents, peer-reviewed manuscripts, reviews and book chapters, and serves as Secretary and Board Member of the Cancer Molecular Therapeutics Research Association.
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com
Join our conversation on Twitter @FORMAInc.
For FORMA Therapeutics
Kari Watson +1 781-235-3060
MacDougall Biomedical Communications